

A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in *Caenorhabditis elegans*

Suzanne Paradis,¹ Michael Ailion,² Alex Toker,³ James H. Thomas,^{2,4} and Gary Ruvkun^{1,5}

¹Department of Molecular Biology, Massachusetts General Hospital, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02114 USA; ²Molecular and Cellular Biology Program of the University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington 98195 USA; ³Signal Transduction Group, Boston Biomedical Research Institute, Boston, Massachusetts 02114 USA; ⁴Department of Genetics, University of Washington, Seattle, Washington 98195 USA

An insulin receptor-like signaling pathway regulates *Caenorhabditis elegans* metabolism, development, and longevity. Inactivation of the insulin receptor homolog DAF-2, the AGE-1 PI3K, or the AKT-1 and AKT-2 kinases causes a developmental arrest at the dauer stage. A null mutation in the *daf-16* Fork head transcription factor alleviates the requirement for signaling through this pathway. We show here that a loss-of-function mutation in *pdk-1*, the *C. elegans* homolog of the mammalian Akt/PKB kinase PDK1, results in constitutive arrest at the dauer stage and increased life span; these phenotypes are suppressed by a loss of function mutation in *daf-16*. An activating mutation in *pdk-1* or overexpression of wild-type *pdk-1* relieves the requirement for AGE-1 PI3K signaling. Therefore, *pdk-1* activity is both necessary and sufficient to propagate AGE-1 PI3K signals in the DAF-2 insulin receptor-like signaling pathway. The activating mutation in *pdk-1* requires *akt-1* and *akt-2* gene activity in order to suppress the dauer arrest phenotype of *age-1*. This indicates that the major function of *C. elegans* PDK1 is to transduce signals from AGE-1 to AKT-1 and AKT-2. The activating *pdk-1* mutation is located in a conserved region of the kinase domain; the equivalent amino acid substitution in human PDK1 activates its kinase activity toward mammalian Akt/PKB.

[Key Words: Insulin signaling; dauer; PDK1 activation; PDK-1; life span]

Received February 26, 1999; revised version accepted April 20, 1999.

Insulin signaling in mammals causes a variety of cellular responses, including glucose uptake and glycogen synthesis in liver and muscle, fat storage in adipocytes, and changes in protein synthesis and gene expression (Kahn 1994). Activation of the insulin receptor leads to activation of other signaling molecules such as phosphoinositide-3-OH kinase (PI3K) and Ras and their downstream effectors, such as Akt/PKB and the MAP kinase cascade (Avruch 1998). The kinase cascades in turn regulate glucose transporter localization, metabolic enzymes, and the transcription and translation of these and other genes (Avruch 1998). In *Caenorhabditis elegans*, a signal transduction cascade from the DAF-2 insulin/IGF-1 receptor homolog (Kimura et al. 1997) to the DAF-16 Fork head transcription factor (Lin et al. 1997; Ogg et al. 1997) regulates metabolism, development, and longevity. Genetic analysis of this pathway has identified homologs of genes that had been implicated in mammalian insulin

signaling by biochemical analyses (Morris et al. 1996; Avruch 1998; Paradis and Ruvkun 1998; this report), demonstrating the extensive conservation of this pathway between *C. elegans* and mammals. In addition, the *C. elegans* genetics has identified new signaling components, such as the DAF-16 Fork head transcription factor (Lin et al. 1997; Ogg et al. 1997) and the DAF-18 PTEN homolog (Ogg and Ruvkun 1998) not previously known to be coupled to insulin. For both the novel genes and the genes implicated previously in insulin signaling, genetic analysis in *C. elegans* allows specific components of the insulin-like signaling pathway to be disrupted so that the metabolic and developmental consequences can be monitored in the whole animal.

The *C. elegans* insulin/IGF-1 receptor pathway is required for reproductive growth and metabolism, as well as normal life span. Reduction of signaling through the DAF-2 insulin receptor-like signaling pathway causes the animals to arrest at a reversible diapause stage known as the dauer larval stage (Kimura et al. 1997). Dauer larvae do not feed or reproduce and their metabolism is shifted to energy storage (O'Riordan and Burnell

⁵Corresponding author.
E-MAIL Ruvkun@frodo.mgh.harvard.edu; FAX (617) 726-6893.

1989, 1990; Riddle and Albert 1997). Molecules that have been identified downstream of the DAF-2 insulin/IGF-1 receptor in *C. elegans* include the AGE-1 PI3K (Morris et al. 1996), the Akt/PKB homologs AKT-1 and AKT-2 (Paradis and Ruvkun 1998), the DAF-18 PTEN phosphatase (Ogg and Ruvkun 1998), and the DAF-16 Fork head/winged helix transcription factor family member (Lin et al. 1997; Ogg et al. 1997). Reducing the activity of *daf-2* or genes that are positively regulated by *daf-2* such as *age-1*, or *akt-1* and *akt-2*, causes *C. elegans* to arrest at the dauer stage constitutively (Morris et al. 1996; Kimura et al. 1997; Paradis and Ruvkun 1998). Reduction-of-function mutations in genes that antagonize *daf-2* and/or *age-1* signaling, such as the *daf-18* PTEN lipid phosphatase and the *daf-16* transcription factor, suppress the dauer constitutive phenotype of *daf-2* and/or *age-1* mutants (Lin et al. 1997; Ogg et al. 1997; Ogg and Ruvkun 1998). Whereas a severe reduction in insulin receptor-like signaling induces arrest at the dauer stage, *daf-2* and *age-1* mutants that have been supplied with these gene activities until after the dauer arrest decision point show an increased life span that is dependent on *daf-16* (Kenyon et al. 1993; Larsen et al. 1995; Morris et al. 1996).

In mammalian insulin signaling, insulin receptor activation leads to activation of PI3K and other signaling molecules (Avruch 1998). Activated PI3K generates 3-phosphoinositides, such as phosphatidylinositol-3,4-bisphosphate (PtdIns-3,4-P2), and phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3), which are thought to act as second messengers in signal transduction cascades because their levels rise rapidly in response to growth factor signaling (Toker and Cantley 1997). PtdIns-3,4-P2 and/or PtdIns-3,4,5-P3 bind to the pleckstrin homology domain of Akt/PKB and are required for its activation (Franke et al. 1997; Frech et al. 1997; Klippel et al. 1997). Phosphoinositide binding is thought to cause Akt/PKB to undergo a conformational change that makes two phosphorylation sites accessible to the pertinent kinases (Alessi et al. 1997b; Stokoe et al. 1997). Activation of Akt/PKB has been implicated in a variety of cellular responses to growth factor signaling, such as protection from apoptosis, glucose transporter translocation, and glycogen synthesis (Cross et al. 1995; Kohn et al. 1996; Dudek et al. 1997; Kauffmann-Zeh et al. 1997; Kulik et al. 1997).

One of the kinases that phosphorylates Akt/PKB and is required for its activation is 3-phosphoinositide-dependent kinase-1 (PDK1) (Alessi et al. 1996; Alessi et al. 1997a,b). PDK1 phosphorylates the Thr-308 site on Akt/PKB in a phosphoinositide dependent manner (Alessi et al. 1997b). Although PDK1 binds PtdIns-3,4-P2 and PtdIns-3,4,5-P3 in vitro (Stephens et al. 1998), it is currently unclear whether the phosphoinositide dependence of Akt/PKB phosphorylation by PDK1 resides solely with the substrate, with PDK1, or with both. Because removal of the pleckstrin homology domain of Akt/PKB relieves the phosphoinositide dependence of PDK1 phosphorylation and PDK1 activity is not increased by growth factors that activate PI3K and Akt/PKB (Alessi et

al. 1997a), it is possible that PDK1 activity is not PtdIns-3,4-P2 or PtdIns-3,4,5-P3 dependent. It has been suggested, however that phosphoinositide binding to PDK1 localizes the kinase to the plasma membrane, thereby co-localizing it with Akt/PKB (Andjelkovic et al. 1997) and increasing Akt/PKB activation (Anderson et al. 1998). The identity of the kinase responsible for the Ser-473 phosphorylation of Akt/PKB (so-called PDK2) is not well established although it has been reported that PDK2 is integrin-linked kinase (ILK) (Delcommenne et al. 1998). *C. elegans* AKT-1 has both the Thr-308 and Ser-473 equivalent phosphorylation sites whereas AKT-2 has only the Thr-308 equivalent site, raising the possibility that these proteins are differentially regulated (Paradis and Ruvkun 1998). PDK1 has also been shown to phosphorylate p70 S6 kinase in a phosphoinositide independent manner, thereby implicating PDK1 in translational control (Alessi et al. 1998; Pullen et al. 1998). More PDK1 substrates have been described recently, including the PKC isoforms ζ and δ (Chou et al. 1998; Le Good et al. 1998) and possibly PKA (Cheng et al. 1998).

Genetic screens for genes that control dauer development have revealed many molecules involved in the DAF-2 insulin receptor-like signal transduction cascade (Riddle et al. 1981; Riddle 1988; Paradis and Ruvkun 1998; this report). Here we report the identification of the *C. elegans* PDK1 homolog *pdk-1*. We establish the action of *pdk-1* in the *C. elegans* insulin receptor-like signaling pathway by analysis of loss-of-function and gain-of-function mutations in *pdk-1*. *pdk-1* activity is required for reproductive growth and metabolism and normal life span; a loss-of-function mutation in the *daf-16* transcription factor bypasses this requirement. Activation of *pdk-1* by substitution of a conserved residue in the kinase domain relieves the requirement for upstream AGE-1 PI3K signaling, but is dependent on *akt-1* and *akt-2* gene activity. The ability of this amino acid substitution to activate PDK1 is conserved across species. These studies of the first mutations in PDK1 in any animal show that *C. elegans pdk-1* gene activity is both necessary and sufficient to propagate AGE-1 PI3K signals in the insulin receptor-like signaling pathway.

Results

Genetic identification of novel loss-of-function and gain-of-function mutations in the C. elegans DAF-2 insulin receptor-like signaling pathway

To identify new components regulating dauer formation, we performed a genetic screen for mutants that arrest at the dauer stage constitutively (Daf-c) at 27°C. Two alleles (*sa680* and *sa709*) from this screen are recessive, map to the left arm of the X chromosome, and fail to complement for the Daf-c phenotype at 27°C, suggesting that they affect the same gene. Whereas both mutations cause a high percentage of dauer arrest at 27°C, the *sa680* mutation also causes a high percentage of dauer arrest at 25°C (Table 1). The Daf-c phenotype of *sa680* can be rescued maternally. An *sa680/+* heterozygote produces

Paradis et al.

Table 1. Effects of *pdk-1(sa680)* and *pdk-1(sa709)* on dauer formation

Genotype	Phenotype at 25.4°C (%)			
	L4 larvae and adult	dauer	dauer-like	no. ^a
<i>pdk-1(sa680)</i>	0	87	13	316
<i>osm-6(p811); pdk-1(sa680)</i>	0	99	1	320
<i>daf-5(e1385); pdk-1(sa680)</i>	0	92	8	205
<i>pdk-1(sa680) daf-12(m20)</i>	100	0	0	232
<i>daf-16(m27); pdk-1(sa680)</i>	99	1 ^b	0	275
<i>akt-1(mg144); pdk-1(sa680)</i>	63	37	1	572
Phenotype at 26.8°C (%)				
Wild type	96	4	0	251
<i>pdk-1(sa709)</i>	3	97	0	116
<i>daf-16(m27)</i>	98	2 ^b	0	258
<i>daf-16(m27); pdk-1(sa709)</i>	98	2 ^b	0	260

See Materials and Methods for description of categories.

^aTotal number of animals scored.^bPartial dauers as described in Vowels and Thomas (1992).

no dauer progeny at 25°C, but ~25% of its progeny (*sa680* homozygotes) produce nearly all dauer progeny at 25°C. *sa680* mutant dauers fail to recover at 15°C in the presence of plentiful food, whereas *sa709* dauers recover readily. These phenotypes are similar to those of *age-1* mutants. *age-1* null mutants have a maternally rescued Daf-c phenotype at all temperatures and are defective in dauer recovery, whereas a weaker *age-1* mutant has a Daf-c phenotype at 27°C and fails to maternally complement *age-1* null mutants (Gottlieb and Ruvkun 1994; Malone et al. 1996; Morris et al. 1996).

In addition to the DAF-2 insulin receptor-like signaling pathway, two other parallel pathways have been implicated in control of dauer arrest (Thomas et al 1993; Gottlieb and Ruvkun 1994). To determine in which of the genetic pathways *sa680* functions, double mutants of *sa680* with mutations that suppress the Daf-c phenotype of mutants in each pathway were analyzed. Mutations in *osm-6* and *daf-5* do not suppress the Daf-c phenotype of *sa680* but mutations in *daf-16* and *daf-12* completely suppress the Daf-c phenotype (Table 1). The suppression of *sa680* by a *daf-16* mutation is consistent with placement of *sa680* in the DAF-2 insulin receptor-like signaling pathway. The suppression by a *daf-12* mutation is distinct from that observed for strong *daf-2* alleles, but has been observed for weak *daf-2* alleles, suggesting that *sa680* only partially abolishes DAF-2 signaling (Gems et al. 1998). In support of the placement of *sa680* in the insulin receptor-like signaling pathway, its Daf-c phenotype is partially suppressed by a gain-of-function mutation in the gene *akt-1* (Table 1) that also suppresses the dauer arrest induced by loss of *age-1* PI3K signaling (Paradis and Ruvkun 1998).

Further genetic mapping of *sa680* placed it on the X chromosome to the right of *unc-1*. Also mapping to this genetic region is *mg142*, a dominant mutation that was isolated in a screen for suppression of the Daf-c phenotype of an *age-1(mg44)* null mutant. Reduction-of-function mutations in *daf-16* and a dominant activating mu-

tation in *akt-1* have also been isolated in this screen (Paradis and Ruvkun 1998). The *mg142* mutation suppresses the dauer constitutive phenotype of two nonsense mutations and one missense mutation in *age-1* and is dominant (Table 2; data not shown). The *mg142* dominant mutation suppresses the *age-1* Daf-c phenotype, whereas the recessive *sa680* and *sa709* mutants phenocopy the *age-1* Daf-c phenotype, suggesting that *mg142* may activate the same gene that is inactivated by *sa680* and *sa709*. The *mg142* mutation does not have an obvious phenotype on its own (Table 2) and animals bearing the mutation arrest as dauer larvae on starved plates. The *mg142* phenotypes are similar to that of the activating mutation in *akt-1* (Paradis and Ruvkun 1998); both mutations activate the insulin signaling pathway enough to bypass the need for AGE-1 1PI3K signaling, but do not activate the pathway to the point that normal dauer arrest is affected strongly.

sa680, *sa709*, and *mg142* are alleles of the *C. elegans* PDK1 homolog

We inspected the *C. elegans* genomic sequence of the region to which these alleles map for genes that have been implicated in receptor tyrosine kinase signaling. The *C. elegans* homolog of human PDK1 (Alessi et al. 1997a,b), which we named *pdk-1*, is located in this region and was an excellent candidate to be the gene defined by these alleles. We determined the *pdk-1* DNA sequence in the *sa680*, *sa709*, and *mg142* strains by PCR amplification and direct sequencing. This revealed a *pdk-1* Gly-295–Arg substitution in the *sa680* strain and a *pdk-1* Ala-303–Val substitution in the *mg142* strain, both conserved residues in the kinase domain (Fig. 1B). We did not detect a mutation in the *pdk-1* coding region in the *sa709* strain; this weak allele may have a mutation in a regulatory region of the gene. The Daf-c phenotypes of *pdk-1(sa680)* and *pdk-1(sa709)* were both efficiently rescued by a *pdk-1(+)* transgene, confirming their assign-

Table 2. Effects of *pdk-1(mg142)* on dauer formation

Genotype of parent	Phenotype of progeny at 25°C at 48 hr post-egglay (%)					no. ^a
	L4 larvae and adult	dauer	dauer-like	dead eggs	other	
Wild type	100	0	0	N.D.	0	471
<i>pdk-1(mg142)</i>	99.7	0	0	0	0.3	329
<i>sqt-1(sc13) age-1(mg44)</i> ^b	0	86.6	0	0.5	12.9 ^c	187
<i>sqt-1(sc13) age-1(mg44); pdk-1(mg142)</i> ^{d,e}	92.6	0	0	0	7.4 ^f	149
<i>daf-16(m27); sqt-1(sc13) age-1(mg44)</i> ^{d,s}	97.6	0	0	0	2.4	376
<i>daf-2(e1370)</i>	0	95.1	0	3.6	1.3	309
<i>daf-2(e1370); pdk-1(mg142)</i> ^h	0	0	94.6	4.6	0.8	240
<i>daf-16(m27); daf-2(e1370)</i> ⁱ	98.1	0	0	1.4	0.5	575

(N.D.) Not determined. See Materials and Methods for description of categories.

^aTotal number of animals scored.

^bThese animals are the homozygous progeny of *age-1*/balancer hermaphrodites.

^cOf 12 animals scored, 10 were dauers and 2 remained arrested at a younger larval stage by 96 hr post-egglay.

^dThese animals are the homozygous *age-1* progeny of homozygous *age-1* hermaphrodites.

^eRescoring of entire assay at 96 hr post-egglay: 50.3% of animals were gravid adults, 44.8% were sterile adults, 0.7% were dauer, and 4.2% were other ($N = 143$); *sqt-1(sc13) age-1(mg44)* animals remained essentially unchanged.

^fSix of seven animals scored were sterile adults and one of seven animals was a dauer by 96 hr post-egglay.

^gRescoring of entire assay at 72 hr post-egglay: 97.1% of animals were gravid adults, 1.8% were sterile adults, and 1.1% were other ($N = 379$).

^hRescoring of entire assay at 96 hr post-egglay: 79.9% of animals were sterile adults, 10.0% were dauer-like, 6.5% were dauers, and 3.5% were other ($N = 229$); *daf-2(e1370)* animals remained essentially unchanged.

ⁱRescoring of entire assay at 72 hr post-egglay: 97.4% of animals were gravid adults, 2.6% were other ($N = 575$).

ment as alleles of *pdk-1* (data not shown; for description of transgene, see Materials and Methods).

The *C. elegans pdk-1* gene has the hallmarks of the PDK1 family including an amino-terminal kinase domain and a carboxy-terminal pleckstrin homology domain (Alessi et al. 1997a) (Fig. 1A). In mammals, PDK1, in conjunction with the phospholipid products of PI3K, activates the Akt/PKB serine/threonine kinase via phosphorylation at the Thr-308 position in response to growth factor signaling (Alessi et al. 1996, 1997a). In *C. elegans*, *akt-1* and *akt-2*, two homologs of Akt/PKB, transduce signals from AGE-1 PI3K to the DAF-16 transcription factor (Paradis and Ruvkun 1998). Simultaneous inactivation of *akt-1* and *akt-2* results in a Daf-c phenotype (Table 3; Paradis and Ruvkun 1998) and an activating mutation in *akt-1* alleviates the need for AGE-1 PI3K signaling in *C. elegans* (Paradis and Ruvkun 1998). Therefore, a loss-of-function mutation in *pdk-1* would be predicted to be unable to activate Akt/PKB and result in a Daf-c phenotype. An activating mutation in *pdk-1* would be predicted to lead to increased *akt-1* and/or *akt-2* activity, thereby suppressing an *age-1* null mutation. These predictions are supported by the observed phenotypes of the *pdk-1* mutants.

To confirm that the *pdk-1(mg142)* mutation causes the dominant suppression of the Daf-c phenotype of *age-1* loss-of-function mutants, we performed a reversion experiment using RNA interference (RNAi) (Fire et al. 1998) to decrease *pdk-1* gene activity in the *age-1(mg44); pdk-1(mg142)* strain. If a mutation in the *pdk-1* locus is responsible for the suppression phenotype observed in this strain, RNAi of *pdk-1* in this strain should revert the suppression phenotype and result in the *age-1*

Daf-c phenotype. Inhibition of *pdk-1* activity by RNAi in the *age-1(mg44); pdk-1(mg142)* strain reverts the *pdk-1* suppression phenotype (Table 3). We conclude that *mg142* is a lesion in the *pdk-1* locus. Reversion of the *pdk-1(mg142)* suppression phenotype also supports the conclusion that *mg142* is a gain-of-function mutation in *pdk-1* rather than a loss-of-function mutation.

Interestingly, reducing *pdk-1* function by RNAi in wild-type animals (Table 3) does not cause a Daf-c phenotype similar to either *pdk-1* loss of function allele. One possible explanation for this result is that RNAi of *pdk-1* does not decrease *pdk-1* gene activity sufficiently to cause a Daf-c phenotype in a wild-type background. However, RNAi of *pdk-1(mg142)* decreases gene activity enough to revert the ability of this gain-of-function allele to suppress the *age-1* Daf-c phenotype (Table 3). Therefore, the possibility existed that RNAi of *pdk-1* actually abolishes *pdk-1* gene activity but *pdk-1(sa680)* was a novel, recessive interfering mutation rather than a loss-of-function mutation. If this were the case, inhibition of *pdk-1* gene activity by RNAi would be expected to revert the Daf-c phenotype of *pdk-1(sa680)*. We performed this experiment and did not observe any reversion of the *pdk-1(sa680)* Daf-c phenotype (data not shown). Therefore, we conclude that *pdk-1(sa680)* is a loss-of-function mutation and that RNAi of *pdk-1* inhibits *pdk-1* gene activity to a lesser extent than *pdk-1(sa680)*. Inhibition of *pdk-1* gene activity by RNAi also fails to enhance the *pdk-1(sa680)* Daf-c phenotype (data not shown). This implies that *pdk-1(sa680)* is a strong and possibly null allele, but because the *sa680* mutation causes an amino acid substitution, *pdk-1(sa680)* could retain some activity.




Figure 1. *pdk-1* encodes a serine/threonine kinase. (A, top) Genetic and physical map of the *pdk-1* region. *pdk-1* is contained on fosmids H42K12 and H33H01. The starting methionine of PDK-1 is at 9848 bp on H42K12, the PDK-1 stop codon is at 3082 bp on H33H01; the fosmids overlap for 1201 bp (from 12897 to end on fosmid H42K12). (Bottom) Exon/intron structure of *pdk-1*. Coding regions are solid boxes; noncoding regions are open boxes; introns are lines. The kinase domain is indicated by hatched boxes (Hanks and Hunter 1995); the pleckstrin homology domain is indicated by the shaded boxes (Alessi et al. 1997a). (B) PDK-1a (GenBank accession no. AF130406); PDK1b (no. AF130407), DMSTPK61 (EMBL Y07908), and human PDK1 (GenBank accession no. AF017995) were aligned using PILEUP (GCG) (accession numbers for the proteins used in the PILEUP are indicated in parentheses). Identical residues are indicated by dots; gaps introduced to align the sequence are indicated by dashes. The kinase domain is indicated by the amino-terminal shaded area and the pleckstrin homology domain is indicated by the carboxy-terminal shaded area. The *sa680* Gly-295–Arg substitution is indicated by an R above the PDK1a sequence. The *mg142* Ala-303–Val substitution is indicated by a V above the PDK1a sequence.

Increased gene dosage of *pdk-1(+)* has a similar genetic activity to the *pdk-1(mg142)* mutation, suggesting that the phenotype of *pdk-1(mg142)* is attributable to an increase in gene activity. Increased gene dosage of *pdk-1(+)* suppresses the Daf-c phenotype of *age-1(mg44)* (Table 4). This suppression is dependent on a functional PDK1 kinase domain because a transgene bearing a substitution of a conserved lysine residue with asparagine (K98N in PDK1a) that inactivates the kinase activity of PDK1 is not able to suppress *age-1(mg44)* (Table 4). Similarly, increased *akt-1* gene dosage was also sufficient to suppress *age-1(mg44)* (Table 4). Our conclusion is that increasing the gene dosage of *pdk-1(+)* is sufficient to compensate for the loss of AGE-1 PI3K signaling, presumably by increasing *akt-1* and/or *akt-2* activity. Importantly, the above genetic analyses of *pdk-1* loss-of-function and gain-of-function mutations demonstrate that *pdk-*

1(mg142) is a dominant activating mutation, as opposed to dominant negative or loss of function.

Activated *pdk-1* requires *akt-1* and *akt-2* gene activities

The biochemical studies of Akt/PKB activation by PDK1 (Alessi et al. 1997b; Stokoe et al. 1997) predict that *pdk-1(mg142)* suppression of the Daf-c phenotype of *age-1* mutants requires *akt-1* and *akt-2* gene activities. Reduction of *akt-1* gene activity alone by RNAi was sufficient to interfere with *pdk-1(mg142)* suppression of the *age-1* Daf-c phenotype (Table 3). Reduction of only *akt-2* gene activity partially impaired the ability of *pdk-1(mg142)* to suppress *age-1(mg44)* (Table 3). Simultaneous inactivation of *akt-1* and *akt-2* by RNAi causes a Daf-c phenotype (Table 3; Paradis and Ruvkun 1998) that is epistatic

Table 3. Effects of *pdk-1*(RNAi), *akt-1*(RNAi), and *akt-2*(RNAi) on dauer formation

Strain	dsRNA injected	Phenotype of progeny at 20°C (%)					no. ^a
		L4 larvae and adult	dauer	dauer-like	dead eggs	other	
<i>age-1(mg44)</i>	uninjected	0	88.8	0	3.8	7.4	598
<i>age-1(mg44); pdk-1(mg142)</i>	uninjected	92.4	0	0	2.3	5.3	1325
<i>age-1(mg44); pdk-1(mg142)</i>	<i>pdk-1</i>	9.8	85.1	2.3	1.2	1.6	686
<i>age-1(mg44); pdk-1(mg142)</i>	<i>akt-1</i>	0	95.6	0	0.5	3.8	182
<i>age-1(mg44); pdk-1(mg142)^b</i>	<i>akt-2</i>	32.7	49.7	13.0	1.3	3.2	684
<i>age-1(mg44); pdk-1(mg142)</i>	<i>akt-1 + akt-2</i>	0	96.1	0	1.1	2.8	280
<i>age-1(mg44); akt-1(mg144)</i>	uninjected	97.2	0	0	0.5	2.3	1485
<i>age-1(mg44); akt-1(mg144)</i>	<i>akt-1</i>	0	91.3	0	0.3	8.4	311
<i>age-1(mg44); akt-1(mg144)</i>	<i>akt-2</i>	62.8	24.8	11.7	0.4	0.4	537
<i>age-1(mg44); akt-1(mg144)</i>	<i>pdk-1</i>	5.7	92.8	0.2	1.0	0.2	873
Wild type ^c	<i>pdk-1</i>	86.4	4.9	4.1	4.6	N.D.	368
Wild type ^d	<i>akt-1</i>	98.9	0	0	1.1	N.D.	542
Wild type ^d	<i>akt-2</i>	97.3	0	0	2.7	N.D.	598

Phenotype of progeny at 26°C (%)							
Wild type	uninjected	98.6	0	0	1.4	N.D.	497
Wild type ^c	<i>akt-1 + akt-2</i>	22.9	64.8	8.1	0.5	3.6	580
<i>pdk-1(mg142)</i>	uninjected	100	0	0	0	N.D.	576
<i>pdk-1(mg142)</i>	<i>akt-1 + akt-2</i>	15.9	77.4	2.2	1.2	3.3	674

(N.D.) Not determined. See Materials and Methods for description of categories. All *age-1* strains also contained the linked *sqt-1(sc13)* mutation.

^aTotal number of animals scored.

^bOverall, the dauer-inducing ability of this RNA in this strain background was variable between injected animals in a given trial and between trials. Animals that looked like dauer or dauer-like at 48 hr frequently became sterile or gravid adults by 72 hr.

^cThis assay was performed at 27°C, a condition that is more dauer-inducing than 20°C. Uninjected wild-type control made 0.2% dauer at 27°C.

^dData reproduced from Paradis and Ruvkun (1998) to facilitate comparison with new data. This assay was performed at 25°C, a condition that is more dauer-inducing than 20°C.

^eThese data differs slightly from results published previously (Paradis and Ruvkun 1998). We believe this is due to differences in strain backgrounds and incubator temperatures [see Materials and Methods].

to the activating mutation *pdk-1(mg142)* (Table 3), suggesting that *akt-1* and *akt-2* act downstream of *pdk-1*. These results are consistent with the model that *pdk-1(mg142)* activates *akt-1* and *akt-2* signaling in the absence of upstream AGE-1 PI3K inputs. These results

Table 4. Effects of *pdk-1* transgenes on dauer formation

Dauer constitutive mutation	Transgene	Phenotype at 25°C (%)				no. ^a
		L4 larvae and adult	dauer and dauer-like	other		
Wild type	none	100	0	N.D.	218	
Wild type	<i>pdk-1(+)</i>	100	0	N.D.	451	
Wild type	<i>pdk-1(KD)^b</i>	100	0	N.D.	539	
<i>age-1(mg44)</i>	none	0	91.7	8.3	108	
<i>age-1(mg44)</i>	<i>pdk-1(+)</i>	69.9	30.1	N.D.	322	
<i>age-1(mg44)</i>	<i>pdk-1(KD)^b</i>	0	98.1	1.9	207	

See Materials and methods for description of categories. All *age-1* strains also contained the linked *sqt-1(sc13)* mutation.

^aTotal number of transgenic animals scored.

^b*pdk-1(KD)* is a kinase dead mutation that changes a conserved lysine to an asparagine (Chou et al. 1998).

show that *akt-1* and *akt-2* are the major outputs of *pdk-1* signaling.

Biochemical experiments have shown that PDK1 phosphorylation of Thr-308 on Akt/PKB is required for Akt/PKB activity (Alessi et al. 1996, 1997b). We tested whether the activating mutation in *akt-1*, *akt-1(mg144)*, relieves the requirement for the PDK1 phosphorylation event. The *akt-1(mg144)* mutation is able to partially suppress the dauer constitutive phenotype of the *pdk-1(sa680)* loss-of-function mutation (Table 1), showing that *akt-1(mg144)* activity does not require full *pdk-1* activity. This experiment is consistent with the model that *akt-1* acts downstream of *pdk-1*. However, *pdk-1* activity is necessary for activated *akt-1* to signal in the absence of AGE-1 generated phosphoinositide signaling. Inactivation of *pdk-1* by RNAi in an *age-1(mg44); akt-1(mg144)* strain abolishes the ability of *akt-1(mg144)* to suppress the Daf-c phenotype of *age-1(mg44)* (Table 3). This observation contrasts with the ability of activated *akt-1(mg144)* to bypass the requirement for *pdk-1* signaling in a genetic background with normal AGE-1 phosphoinositide signaling (Table 1). One interpretation of this result is that AKT-1 has both non-PDK-1 phosphoinositide dependent and PDK-1 dependent inputs to its

Paradis et al.

normal activation and that the *akt-1(mg144)* mutation relieves the requirement for PDK-1 inputs only if AGE-1 PI3K-generated phosphoinositides are present.

As would be expected for a mutation that is predicted to increase *akt-1* and possibly *akt-2* activity, *pdk-1(mg142)* behaves similarly to the activating mutation in *akt-1*, *akt-1(mg144)* (Paradis and Ruvkun 1998). Like *akt-1(mg144)*, *pdk-1(mg142)* suppresses a null mutation in *age-1* more efficiently than it suppresses a loss-of-function mutation in the DAF-2 insulin receptor-like protein (Table 2). This result supports the idea that a bifurcation in the signaling pathway occurs downstream of the DAF-2 insulin receptor-like homolog, and that the AGE-1 PI3K and its downstream signaling molecules represent one branch of these parallel pathways. All signaling from the DAF-2 insulin receptor-like homolog must converge on *daf-16*, because *daf-16(m27)* completely suppresses the *Daf-c* phenotypes of both *daf-2* and *age-1* mutants (Table 2) (Vowels and Thomas 1992; Gottlieb and Ruvkun 1994; Larsen et al. 1995).

A human PDK1 Ala-277-Val mutant that is equivalent to pdk-1(mg142) activates PDK1 kinase activity toward Akt/PKB

The genetic evidence that the *pdk-1(mg142)* mutation activates PDK1 kinase activity toward Akt/PKB was biochemically verified using the mammalian homologs of these kinases. The Ala-303-Val substitution in *pdk-1(mg142)* is in a region of the kinase domain that is conserved in human PDK1 (hPDK1) (Fig. 1B). The equivalent substitution mutation was constructed in hPDK1 (hPDK1.A277V) and its kinase activity on mammalian Akt/PKB substrate was compared with wild-type hPDK1. Human embryonic 293T kidney cells were transfected transiently with wild-type hPDK1, a kinase inactive mutant hPDK1.K110N (Chou et al. 1998) and the hPDK1.A277V mutant, all tagged with a Myc epitope. Transfected cells were lysed under native conditions, and the hPDK1 proteins were immunoprecipitated with a monoclonal anti-Myc antibody. The activity of each hPDK1 protein derivative was determined in an in vitro protein kinase assay using recombinant His-tagged Akt/PKB substrate in the presence of PtdIns-3,4,5-P₃, as described previously (Chou et al. 1998) (Fig. 2A). The hPDK1.A277V mutant has a significantly higher protein kinase activity (2.9-fold) toward the Akt/PKB substrate than wild-type hPDK1 (Fig. 2A). As expected, the kinase-inactive mutant poorly phosphorylates the substrate (Fig. 2A). This confirms biochemically the genetic evidence that an Ala-to-Val substitution at this conserved position increases PDK1 protein kinase activity. In addition, we noted that the hPDK1.A277V mutation induces a gel-mobility shift reminiscent of the hyperphosphorylation found in other signaling protein kinases, such as p70 S6 kinase (Romanelli et al. 1999; Fig. 2B). This presumed phosphorylation of hPDK1 may be indicative of activation of the enzyme. It remains to be established, however, whether this modification applies only to the




Figure 2. Substitution of A277V in human PDK1 leads to activation of the enzyme. Wild-type human PDK1 (hPDK1), kinase inactive hPDK1 (hPDK1.K110N), and the activating A277V mutation in hPDK1 (hPDK1.A277V) expression clones were transfected transiently in duplicate into 293T cells and after the transfection protocol, the protein kinase activity of each mutant toward Akt/PKB was assayed in an in vitro protein kinase assay (see Material and Methods). The data are representative of four independent experiments. (A) Relative amounts of hPDK1 proteins (hPDK1, hPDK1.K110N, and hPDK1.A277V) were normalized for hPDK1 protein concentration from B using anti-Myc antibody and ECL detection (Amersham) on a Bio-Rad Molecular Imager, and the adjusted amounts of lysate used for immunoprecipitation with anti-Myc antibody. The immunoprecipitates were washed and an in vitro kinase assay using His-Akt as substrate was carried out. The phosphorylation of Akt/PKB (His-Akt) was assessed by autoradiography and quantitated on a Bio-Rad Molecular Imager. The data are normalized to wild-type hPDK1 activity (1) and represent the average of the two lanes for each hPDK1 construct. In the hPDK1.A277V lanes, only the lower species (comigrating with His-Akt in the wild-type hPDK1 lanes) were used for quantitation as the identity of the higher migrating species is unclear. (B) Total cell lysate was assayed for total protein content (Bio-Rad Protein Assay) and equal amounts of protein loaded on a 7.5% SDS-polyacrylamide gel, and resolved proteins transferred to nitrocellulose and immunoblotted with anti-Myc antibody. Additional anti-Myc immunoreactive bands are observed with the A277V mutant when compared with either wild-type or kinase-inactive proteins.

Ala-277-Val-activating mutation or is a more general mechanism of hPDK1 activation by upstream signaling proteins.

pdk-1(sa680) extends C. elegans life span

Mutations in *age-1* increase *C. elegans* life span greater than twofold (Klass 1983; Larsen et al. 1995; Morris et al. 1996). Mutations in *daf-16* suppress this life span increase (Kenyon et al. 1993; Larsen et al. 1995). A loss-of-function mutation in *pdk-1* increases *C. elegans* life span almost twofold, similarly to a mutation in *age-1* (Fig. 3). *daf-16(m27)* suppresses the longevity phenotype of *pdk-1(sa680)* (Fig. 3). These results show that longevity regulation signals from the DAF-2 and AGE-1 signaling pathway are propagated by PKD-1, presumably via AKT-1 and AKT-2, to the DAF-16 transcription factor. Interestingly, both *daf-16(m27)*; *pdk-1(sa680)* and the activating mutation in *pdk-1* on its own have a slightly shortened

C. elegans PDK1 transduces AGE-1 PI3 kinase signals




Figure 3. Adult life span of *pdk-1(sa680)* mutants. *pdk-1(sa680)* extends adult life span and a mutation in *daf-16* suppresses the life span increase at 25°C. Mean life spans were 17 days for wild type (□, *n* = 50), 15 days for *pdk-1(mg142)* (★, *n* = 50), 15 days for *daf-16(m27)*; *pdk-1(sa680)* (●, *n* = 49), 27 days for *pdk-1(sa680)* (◇, *n* = 50), 27 days for *sqt-1(sc13) age-1(hx546)* (—, *n* = 25). Mean life spans are significantly different ($P \leq 2e-9$; see Materials and Methods) from each other except *pdk-1(sa680)* compared with *sqt-1(sc13) age-1(hx546)*, and *daf-16(m27)*; *pdk-1(sa680)* compared with *pdk-1(mg142)*. Life spans were determined in parallel for all strains; data is from one representative experiment that has been performed at least one other time.

life span relative to wild type (Fig. 3). This result agrees with previously published results showing decreased longevity in a *daf-16(m26)* mutant strain (Larsen et al. 1995). The significance of a slightly decreased life span of a particular strain, however, is difficult to interpret because strain-to-strain variation has been observed even between different wild-type isolates (Kenyon 1997). Therefore, a more rigorous analysis would have to be performed to conclude that the small decrease in life span observed in these strains is caused by these particular mutations.

The activating mutation *pdk-1(mg142)* does not suppress the increased longevity phenotype of *age-1* (data not shown). The activating mutation in *akt-1* also does not suppress the life span increase of *age-1* mutants (Paradis and Ruvkun 1998). One possible interpretation of this data is that the degree of pathway activation by *pdk-1(mg142)* or *akt-1(mg144)* in the absence of normal PtdIns-3,4-P2 and PtdIns-3,4,5-P3 signaling is enough to bypass the need for AGE-1 PI3K signaling in reproductive development but not in life span. Animals carrying only a maternal contribution of *age-1* activity are long lived but do not arrest at the dauer stage (Morris et al. 1996), which is consistent with the model that a wild-type life span demands a higher level of pathway activation.

pdk-1 loss-of-function mutants have pleiotropic phenotypes

pdk-1(sa680) and *pdk-1(sa709)* mutants have several other pleiotropic phenotypes in addition to the Daf-c and aging phenotypes (Table 5). *pdk-1(sa680)* mutant animals grown at 20°C are defective in egg-laying (Egl), have a longer body than wild type (Lon), form clumps of animals rather than being dispersed on the bacterial lawn (Cpy) (Thomas et al. 1993), and have low fertility. Like the Daf-c phenotype, the Lon, Cpy, and fertility phenotypes of *pdk-1(sa680)* are rescued maternally. The *pdk-1(sa680)* Egl phenotype, however, does not show complete maternal rescue. A mutation in *daf-16* suppresses all of the phenotypes and the *akt-1(mg144)* mutation partially suppresses the Daf-c and fertility phenotypes, but does not suppress the Egl, Lon, and Cpy phenotypes (though partial suppression of these qualitative phenotypes might be difficult to score accurately). Both the weaker suppression of the Daf-c phenotype and the lack of suppression of the Egl, Lon, and Cpy phenotypes by the *akt-1(mg144)* activating mutation could reflect weaker activation of the pathway by *akt-1(mg144)* than by *daf-16(m27)*. Alternatively, *pdk-1(sa680)* could have outputs in parallel to AKT-1 that are not activated by *akt-1(mg144)* but that converge on DAF-16.

Table 5. Summary of *pdk-1* loss-of-function phenotypes

Genotype	Daf-c	Egl	Lon	Cpy	Brood size at 20°C ^a
Wild type	+	+	+	+	291 ± 69 (5)
<i>pdk-1(sa709)</i>	+/- ^b	+/- ^b	-	+/- ^b	N.D. ^c
<i>pdk-1(sa680)</i>	-	-	-	-	24 ± 20 (4)
<i>osm-6(p811); pdk-1(sa680)</i>	-	-	-	-	38 ± 17 (5)
<i>daf-5(e1385); pdk-1(sa680)</i>	-	-	-	-	36 ± 23 (5)
<i>pdk-1(sa680) daf-12(m20)</i>	+	-	-	-	17 ± 16 (5)
<i>daf-16(m27); pdk-1(sa680)</i>	+	+	+	+	230 ± 43 (5)
<i>akt-1(mg144); pdk-1(sa680)</i>	+/- ^d	-	-	-	135 ± 61 (3)

^aMean brood size ± S.D. with the number of animals assayed in parentheses.

^bIndicates that *pdk-1(sa709)* has defective phenotypes that are weaker than those of *pdk-1(sa680)*.

^cNot determined. However, casual observation suggests that *pdk-1(sa709)* does not have an obvious fertility defect.

^dPartial suppression of the Daf-c phenotype.

PDK-1/GFP is widely expressed

The expression pattern of *pdk-1* was examined in transgenic animals containing a translational fusion of the genomic *pdk-1* locus to green fluorescent protein (GFP) (Chalfie et al. 1994). This construct contains the entire genomic coding region from *pdk-1*, including 5' upstream regulatory sequences, fused in frame at the carboxyl terminus to GFP. The PDK-1/GFP fusion efficiently rescues the Daf-c phenotype of *pdk-1(sa680)*, indicating that the fusion protein is functional (data not shown). PDK-1/GFP expression is observed in late stage embryos and throughout the life of the animal. In post-embryonic animals, PDK-1/GFP expression is observed in the cell bodies and processes of the majority of neurons in the head and tail (Fig. 4A), in the motor neurons of the ventral nerve cord (Fig. 4B) and neuronal processes along the body of the animal, in the cells and neurons of the pharynx (Fig. 4A), in intestinal cells (Fig. 4B), and in hypodermal cells (Fig. 4A). In L4s and adults, PDK-1/GFP is also expressed in the somatic gonad (data not shown).

The PDK-1/GFP expression pattern is similar to the expression patterns of AKT-1/GFP and AKT-2/GFP (Paradis and Ruvkun 1998). This result is consistent with a role for PDK-1 in activating AKT-1 and AKT-2. The broad expression patterns of these genes are consistent with a function in the sensory neurons that regulate dauer formation (Bargmann and Horvitz 1991) or in the




Figure 4. PDK-1/GFP expression. (A) PDK-1/GFP expression in an L1 animal. Expression in the procorpus and anterior bulb of the pharynx (ant.ph.) is shown; expression in the entire pharynx is also observed. PDK-1/GFP expression in the cell bodies of many neurons in the head and tail is visible; occasional expression in neuronal nuclei is observed. Expression of PDK-1/GFP is also observed in the hypodermal cells (hyp) of the tail. (B) PDK-1/GFP expression in the intestine (int.) and ventral nerve cord (VNC) of an L1 animal. Anterior is to the left, ventral is down; the animal is slightly twisted because of co-injection with the *rol-6* marker. Cell bodies and axons of the VNC neurons (arrowheads) clearly express PDK-1/GFP as do the cell bodies of the intestinal cells (arrows); VNC and intestinal nuclei do not appear to express PDK-1/GFP.

target tissues that are remodeled during dauer development, such as the pharynx, hypodermis, and intestine (Riddle and Albert 1997).

Discussion

The *C. elegans* PDK1 homolog is required to prevent developmental arrest at the dauer larval stage. Loss-of-function mutations in *pdk-1* cause a dauer constitutive phenotype and life span increase that are suppressed by loss-of-function mutations in the *daf-16* transcription factor. This confirms the placement of *pdk-1* in the DAF-2 insulin receptor-like signaling pathway and indicates that the DAF-16 transcription factor is a major output of PDK1 signaling in *C. elegans*. An activating mutation in *pdk-1* is sufficient to efficiently bypass the need for AGE-1 PI3K signaling in reproductive development. In agreement with the model that PDK1 activates Akt/PKB signaling, the ability of the activating mutation in *pdk-1* to suppress the dauer constitutive phenotype of a null *age-1* PI3K mutant is dependent on *akt-1* and partially dependent on *akt-2*. This shows that *pdk-1* functions between AGE-1 PI3K and AKT-1/AKT-2 to transduce insulin receptor-like signals and promote reproductive growth and metabolism. PDK-1 probably does not directly phosphorylate DAF-16 because DAF-16 does not have PDK1 consensus phosphorylation sites (TFCGT; Chou et al. 1998). The direct PDK-1 targets are more likely to be AKT-1 and AKT-2 that bear this consensus phosphorylation site and act downstream of PDK-1. DAF-16 does have Akt/PKB consensus phosphorylation sites suggesting that it is directly regulated by Akt/PKB phosphorylation (Paradis and Ruvkun 1998). In support of this model, it was shown recently that Akt/PKB phosphorylation of a mammalian homolog of DAF-16 inhibits its nuclear localization and transcriptional activity and promotes cell survival (Brunet et al. 1999).

PDK1 is required for Akt/PKB activation in other systems (Alessi et al. 1996, 1997b). It is known that simultaneous reduction of *akt-1* and *akt-2* gene activity causes dauer arrest in *C. elegans* (Paradis and Ruvkun 1998). Our genetic analyses also predict that the reduction of function mutations in *pdk-1* impair its ability to activate *akt-1* and *akt-2*, thereby resulting in a dauer constitutive phenotype. Because reduction of *akt-1* and *akt-2* gene activity is epistatic to the activating mutation in *pdk-1*, it appears that *akt-1* and *akt-2* are the relevant outputs of *pdk-1* in regulating the growth arrest and metabolic shift associated with dauer arrest. PDK1 also has other known outputs in mammals, such as p70 S6 kinase (Alessi et al. 1998; Pullen et al. 1998) and PKC isotypes ζ and δ (Chou et al. 1998; Le Good et al. 1998). The suppression of the activated *pdk-1(mg142)* phenotype by inhibition of *akt-1* and *akt-2* gene activities strongly argues that these other possible PDK1 outputs are not relevant to the regulation of dauer arrest by *pdk-1*. So far, none of these other molecules has been implicated by genetic analysis in the DAF-2 insulin receptor-like signaling pathway.

The *pdk-1* loss-of-function and gain-of-function mutations that map to conserved residues in the kinase do-

main of the protein can be interpreted in light of the known crystal structure of the homologous mammalian PKA kinase (Zheng et al. 1993). The Gly-295 residue changed to Arg in *pdk-1(sa680)* (Fig. 1B) is located in subdomain IX (Hanks and Hunter 1995) of the kinase domain and is conserved completely in all PDK1 family members and well conserved in serine/threonine kinases in general. This conserved glycine is located in α -helix F buried deep within the kinase domain (Zheng et al. 1993). Therefore a Gly-to-Arg substitution at this position would be predicted to interfere with kinase domain tertiary structure and reduce kinase activity. Our genetic analysis is consistent with *sa680* being a severe loss-of-function mutation in *pdk-1*.

The Ala-303 residue changed to Val in the dominant-activating *pdk-1(mg142)* allele is also a conserved residue in subdomain IX of the kinase domain of PDK-1 (Fig. 1B) predicted to lie in α -helix F only eight amino acids away from Gly-295. The alanine residue is conserved in all PDK1 family members but is not conserved in all serine/threonine kinase domains. Other PKA and PKC family members have a valine at that position, as do other serine/threonine kinase family members, suggesting that this mutation does not interfere with kinase activity. In fact, the equivalent amino acid substitution in human PDK1 (Ala-277-Val) increases human PDK1 kinase activity relative to hPDK1 wild-type kinase activity. This result agrees with our genetic analysis, which shows that *pdk-1(mg142)* is an activating mutation and implies that the function of alanine at this position is conserved across species.

The fact that an Ala-to-Val substitution at this position (*C. elegans* 303/human 277) results in an activated kinase indicates that Ala-303/277 may normally limit PDK1 activity. Ala-303/277 may function simply to reduce PDK1 activity at all times, or more interestingly, it may down-regulate PDK1 activity only in the absence of PtdIns-3,4-P2 and PtdIns-3,4,5-P3 signals. Isolation of the activating Ala-303-Val substitution in *C. elegans* PDK-1, and the demonstration that the equivalent substitution activates human PDK1, shows that PDK1 can be activated above its basal level. So far, PDK1 had been refractive to additional activation on treatment with stimuli that activate Akt/PKB (Alessi et al. 1997a).

Based on analogy to the known PKA kinase domain crystal structure, Ala-303/277 is solvent exposed and on the same face as the pseudosubstrate binding region of PKA (1CMK; Zheng et al. 1993). There are two simple models for how the Ala-303/277-Val substitution activates PDK1. One possibility is that Val-303/277, either directly or indirectly perhaps via α -helix F movement, increases recognition and/or phosphorylation of substrates by PDK1. A related idea is that Val-303/277 increases recognition of the phosphoinositides or other upstream regulatory molecules for PDK1 itself. Another possibility is that Val-303/277 interferes with an inhibitory interaction, for example with a pseudosubstrate, that normally decreases PDK1 phosphorylation of substrates. The mobility shift observed with hPDK1.A277V

that is suggestive of hyperphosphorylation of the protein supports either model.

An activating mutation in *pdk-1* or overexpressing *pdk-1(+)* bypasses the need for AGE-1 PI3K signaling. The current model for Akt/PKB activation is that PtdIns-3,4-P2 and/or PtdIns-3,4,5-P3 bind to the pleckstrin homology domain of Akt/PKB, thereby making the Thr-308 site accessible to phosphorylation by PDK1, and possibly also serving to localize the protein to the cell membrane (Alessi et al. 1997b; Andjelkovic et al. 1997; Stokoe et al. 1997; Anderson et al. 1998). Our results are consistent with both possibilities. The role of the phosphoinositides in activating PDK1 has not been established at present; our genetic analysis shows that *pdk-1* is a downstream target of AGE-1 PI3K. Whereas the *pdk-1* gain-of-function mutation bypasses the requirement for AGE-1-mediated PtdIns-3,4-P2 and PtdIns-3,4,5-P3 production, it is unlikely that AGE-1 PI3K is the only source for PtdIns-3,4-P2 and PtdIns-3,4,5-P3 in the cell. The fact that inactivation of the DAF-18 PTEN lipid phosphatase can suppress null mutations in AGE-1 PI3K (Ogg and Ruvkun 1998) suggests that there is another source of PtdIns-3,4-P2 and PtdIns-3,4,5-P3 in the absence of *age-1* activity. This indicates that the activating mutations in *akt-1* and *pdk-1* do not necessarily activate the proteins in the absence of the phosphoinositides; it is possible that these mutations sensitize the proteins to levels of phosphoinositides that are subthreshold for wild-type AKT-1 and PDK1.

The increased life span observed in animals carrying a loss-of-function *pdk-1* mutation shows that *pdk-1* functions in a major *C. elegans* longevity regulating pathway that includes the DAF-2 insulin receptor-like protein and downstream AGE-1 PI3K (Klass 1983; Larsen et al. 1995; Morris et al. 1996). The dependence of the *pdk-1(sa680)* life span increase on *daf-16* also maps *pdk-1* to this pathway (Kenyon et al. 1993; Larsen et al. 1995). One popular theory is that aging results from reactive oxygen species inflicting damage on cellular proteins and nucleic acids; therefore molecules that neutralize reactive oxygen species would be protective against aging (Sohal and Weindruch 1996). It is not clear how mis-regulated *daf-16* activity results in increased life span. One possibility is that *daf-16* activates transcription of genes that promote longevity in the organism. In support of this idea, *age-1* mutant animals (which have mis-regulated *daf-16* activity similar to *pdk-1(sa680)* animals) have increased activity of superoxide dismutase and catalase (Larsen 1993), two proteins implicated in scavenging reactive oxygen species. *daf-16* could promote longevity by activating the transcription of superoxide dismutase and catalase genes, thereby increasing the ability of *C. elegans* to protect against oxidative damage.

The pleiotropy of the *pdk-1* loss-of-function alleles indicates that *pdk-1* also regulates the signaling pathways that control body size, egg laying, and social behavior. A TGF- β related signaling pathway functions in parallel to the DAF-2 insulin receptor-like signaling pathway to regulate dauer formation (Thomas et al. 1993; Gottlieb and Ruvkun 1994). Mutations in the TGF- β ligand, re-

ceptor, and downstream effectors also result in Daf-c, Egl, and Cpy phenotypes (Estevez et al. 1993; Thomas et al. 1993; Ren et al. 1996). *pdk-1* mutants are the first in the DAF-2 insulin receptor-like signaling pathway to display the Egl and Cpy phenotypes (although *age-1* mutants also appear slightly Egl; data not shown). This suggests that *pdk-1* has outputs to the parallel TGF- β signaling pathway or to targets in common with those regulated by the TGF- β pathway. The fact that a mutation in the *daf-16* transcription factor suppresses all the phenotypes of *pdk-1(sa680)*, however, suggests that these other outputs depend on *daf-16*. Furthermore, the interaction between these pathways may be complex because *daf-5(e1385)* suppresses the pleiotropic phenotypes of mutants in the TGF- β pathway (Thomas et al. 1993) but does not suppress *pdk-1(sa680)* pleiotropies, whereas *daf-16(m27)* suppresses the pleiotropies of *pdk-1(sa680)* but not those of TGF- β pathway mutants (M. Ailion, T. Inoue, and J.H. Thomas, pers. comm.).

The role of *pdk-1* in regulating *akt-1* and *akt-2* activity in the DAF-2 insulin receptor-like signal transduction cascade suggests the following model (Fig. 5). Under reproductive growth conditions an insulin-like ligand binds to and activates the DAF-2 insulin/IGF-I receptor. Activation of DAF-2 recruits and activates the AGE-1 PI3K and other signaling pathways emanating from DAF-2. Our genetic experiments place PDK1 downstream of and positively regulated by AGE-1 PI3K, and upstream of and negatively regulating DAF-16. Although it is a formal possibility that PDK-1 signals in parallel to AKT-1/AKT-2 to antagonize DAF-16, our analysis suggests that PDK-1 is dependent on AKT-1 and AKT-2 to exert its function. Therefore, we favor the model that PDK-1 antagonizes DAF-16 by activating AKT-1 and AKT-2. The phosphoinositides generated by AGE-1 activate PDK1 and, in cooperation with phosphorylation by PDK1 (and the as yet unidentified PDK2), activate AKT-1 and AKT-2. AKT-1 and AKT-2, and presumably inputs from other DAF-2 activated pathways, negatively regulate the DAF-16 transcription factor, possibly via direct phosphorylation of DAF-16. The nuclear localization of the mammalian DAF-16 homolog FKHR11 is an-

tagonized by Akt/PKB signaling (Brunet et al. 1999), consistent with the genetic evidence that *C. elegans* DAF-16 is active when insulin receptor-like signaling is decreased. Unphosphorylated DAF-16 could function to activate genes necessary for dauer arrest, metabolism, and increased life span or could repress genes necessary for reproductive growth.

Biochemical analysis of the insulin signaling pathway suggests that PI3K, PDK1, and Akt/PKB act in the same cell to transduce insulin signals (Kahn 1994; Alessi et al. 1997b; Avruch 1998). Our model is that the DAF-2 insulin receptor-like protein, AGE-1 PI3K, PDK-1, AKT-1/AKT-2, the DAF-18 PTEN phosphatase, and the DAF-16 transcription factor act in the same cell to transduce signals from an as yet unidentified insulin-like ligand to transcriptional outputs regulated by DAF-16 in the nucleus. It has not yet been determined if these genes in fact act in the same cells to regulate dauer formation. Interestingly, DAF-2 has been shown to function cell nonautonomously to regulate dauer formation and longevity (Apfeld and Kenyon 1998). One possible interpretation of this result is that the DAF-2 mediated signal transduction cascade itself generates another signal that controls reproductive growth, metabolism, and life span. This result, however, does not clarify if AGE-1, PDK-1, AKT-1/AKT-2, DAF-18, and DAF-16 function in the same cells as DAF-2 and further functional analysis of these genes is required to address that question. *pdk-1*, *akt-1*, *akt-2*, and *daf-16* are all broadly expressed (Ogg et al. 1997; Paradis and Ruvkun 1998). It is still not understood whether these molecules function in secretory neurons to generate the dauer-inducing signal, or function in the target tissues that are remodeled during dauer formation to receive and respond to the dauer-inducing signal.

Mammalian homologs of many of the genes (*daf-2*, *age-1*, *akt-1*, *akt-2*, *pdk-1*) that regulate *C. elegans* dauer arrest had been shown biochemically to act in the insulin signal transduction cascade (Avruch 1998). Our genetic analysis of *pdk-1* strongly endorses the placement of *pdk-1* in the insulin pathway and also reveals important regulatory regions on the protein. Also, our molecu-




Figure 5. Model for regulation of reproductive growth and metabolism by the DAF-2 insulin receptor-like signaling pathway. On DAF-2 activation, AGE-1 generates PtdIns-3,4-P₂ and PtdIns-3,4,5-P₃ that are required for PDK-1 and AKT-1/AKT-2 activation. Other parallel pathways from DAF-2 are also activated and all signaling converges on DAF-16. See text for details.

C. *elegans* PDK1 transduces AGE-1 PI3 kinase signals

lar and genetic analysis of dauer formation suggests that much of the insulin signaling pathway was in place in the common ancestor of nematodes and vertebrates. The fact that the nematode and mammalian pathways share so many conserved molecules suggests that, as in the case of the DAF-16 transcription factor and DAF-18 phosphatase, a combination of *C. elegans* genetics and the nearly complete genome sequence can reveal new molecules involved in insulin signal transduction.

Materials and methods

Strains and transgenic lines

The following strains were used: Wild type: N2 Bristol, GR1318 *pdk-1(mg142)*, JT9609 *pdk-1(sa680)*, JT9604 *osm-6(p811)*; *pdk-1(sa680)*, JT9606 *daf-5(e1385)*; *pdk-1(sa680)*, JT9605 *pdk-1(sa680) daf-12(m20)*, JT9607 *daf-16(m27)*; *pdk-1(sa680)*, JT10108 *akt-1(mg144)*; *pdk-1(sa680)*, JT709 *pdk-1(sa709)*, JT6064 *daf-16(m27)*, JT9902 *daf-16(m27)*; *pdk-1(sa709)*, GR1188 *sqt-1(sc13) age-1(mg44)/mnC1*, GR1316 *sqt-1(sc13) age-1(mg44)*; *pdk-1(mg142)*, GR1196 *daf-16(m27)*; *sqt-1(sc13) age-1(mg44)*, GR1306 *sqt-1(sc13) age-1(mg44)*; *akt-1(mg144)*, HT211 *sqt-1(sc13) age-1(hx546)*, GR1122 *daf-2(e1370)*, SP122 *daf-2(e1370)*; *pdk-1(mg142)*, GR1105 *daf-16(m27)*; *daf-2(e1370)*, GR1319 *unc-4(e120) age-1(mg44)/mnC1*.

The following transgenic lines were used: SGP300 *mgEx464*, SGP301 *mgEx465*, SGP303 *mgEx467*, SGP304 *mgEx468*, SGP305 *mgEx469*, SGP320 *sqt-1(sc13) age-1(mg44)/+*; *mgEx464*, SGP319 *sqt-1(sc13) age-1(mg44)/+*; *mgEx465*, SGP317 *sqt-1(sc13) age-1(mg44)*; *mgEx467*, SGP316 *sqt-1(sc13) age-1(mg44)*; *mgEx468*, SGP318 *sqt-1(sc13) age-1(mg44)*; *mgEx469*, SGP294 *mgEx479*, SGP295 *mgEx480*, SGP296 *mgEx481*, SGP306 *pdk-1(sa680)*; *mgEx470*, SGP307 *pdk-1(sa680)*; *mgEx471*, SGP308 *pdk-1(sa709)*; *mgEx472*, SGP312 *pdk-1(sa709)*; *mgEx476*, SGP313 *pdk-1(sa709)*; *mgEx477*.

Isolation and mapping of *pdk-1(sa680)* and *pdk-1(sa709)*

pdk-1(sa680) and *pdk-1(sa709)* were isolated in a screen for Daf-c mutants at 27°C. *sa680* was outcrossed four times and *sa709* twice before characterizing the mutant phenotypes in detail. At all temperatures, *sa680* males all arrest as dauers or die before the dauer stage. Therefore, mapping markers were always crossed into the *sa680* mutant, often using *tra-2(q276)* to obtain XX males heterozygous for X chromosome markers. Both *sa680* and *sa709* were mapped to the left arm of the X chromosome between *unc-1* and *dpy-3*. Pooling results from both Unc non-Dpy and Dpy non-Unc recombinants picked from either *sa680/unc-1(e719) dpy-3(e27)*, or *sa709/unc-1(e719) dpy-3(e27)*, we get the following map data: *unc-1* (13) *sa680* (46) *dpy-3*, and *unc-1* (2) *sa709* (8) *dpy-3*. This is very close to the position of *pdk-1* on the physical map.

pdk-1(mg142) isolation and mapping

pdk-1(mg142) was isolated as a suppressor of *age-1(mg44)* in a screen described previously (Paradis and Ruvkun 1998). All mapping experiments were done in a *sqt-1(sc13) age-1(mg44)* mutant background. *age-1(mg44)* causes a Daf-c phenotype that can be rescued maternally (Riddle 1988). Therefore, in each mapping experiment, we first homozygosed *sqt-1 age-1*, then genotyped the other loci by scoring phenotypes segregated in the subsequent generation. For technical reasons, we did not score the subsequent generation of animals that had homozygosed a mapping marker in the same generation as *sqt-1 age-1*

(i.e., we did not score the broods of *sqt-1 age-1; dpy-3*, for example). During backcrossing, we found *pdk-1(mg142)* to be X-linked. Subsequent two-factor crosses showed that *mg142* is linked to *dpy-3(e27)* by roughly 11 m.u. Three-factor crosses between *mg142* and *dpy-6(e14) unc-3(e151)* suggested that *mg142* is to the left of *dpy-6*. Further, three-factor crosses between *mg142* and *unc-1(e719) dpy-7(e88)* showed that *mg142* is either close to the right, or possibly to the left, of *unc-1*. These results are as follows. First, we recovered 42 homozygous *mg142* animals and 19 heterozygous *mg142/unc-1(e719) dpy-7(e88)* animals, representing the nonrecombinant classes. In the recombinant classes, we found that 15 out of 15 Dpy non-Unc recombinants carried *mg142* (although we might have overlooked recombinants that did not carry *mg142* because it is difficult to score Unc in Dpy dauers). This result places *mg142* far from *dpy-7*. Only one out of 15 Unc non-Dpy recombinants carried *mg142*. This result places *mg142* right of and close to *unc-1*, an interpretation that is consistent with the *pdk-1* molecular cloning result. We also isolated two recombinants that carried *mg142 unc-1(e719) dpy-7(e88)* chromosomes, however, suggesting that *mg142* is to the left of *unc-1*. We suspect this class to be the result of double-recombination events. Extrapolation of this data to account for all recombinant and nonrecombinant classes gives a two factor map distance between *mg142* and *unc-1* of 3.3 m.u. or a three-factor map distance for *mg142* of 1.7 m.u. right of *unc-1*.

Test for *pdk-1(mg142)* dominance

unc-4(e120) age-1(mg44)/+ males were crossed to *sqt-1(sc13) age-1(mg44); pdk-1(mg142)* hermaphrodites. In the F₁ we recovered the following cross progeny: 249 wild-type nondauer males; 242 wild-type nondauer hermaphrodites; 10 wild-type dauers; and 13 other (totals are from two trials). The broods of wild-type nondauer hermaphrodites that segregated Sqt, Unc, and wild type were scored for dauer versus non-dauer and gave the following results: 70.6% non-dauer and 29.4% dauer (*n* = 422, one trial). We noticed that the dauers seemed to recover 24–48 hr after scoring in contrast with *age-1(mg44)* dauers. We believe that this is evidence for a maternal effect of *pdk-1(mg142)* suppression of *age-1*.

pdk-1(sa680) and *pdk-1(sa709)* dauer formation assays

Table 1 combines the results from two independent experiments, each with similar results. For *pdk-1(sa680)* dauer formation assays, in one experiment parents were allowed to lay eggs at room temperature for 8 hr and plates were then shifted to 25.4°C. In the second, a 17-hr overnight egg lay was performed at 25.4°C before parents were removed (in this assay, some *sa680* parents had 'bagged' from internal hatching of progeny). In both cases, the plates were counted 48 hr post-egg-lay. Care was taken to examine the sides of the plate, as *sa680* dauers have a high propensity to climb the walls of the plate. Tight synchrony was not needed because of lack of recovery of *sa680* dauers, and the assays were performed as described because *sa680* is defective in egg-laying. In addition to forming dauers, *sa680* mutants form a low percentage of 'dauer-like' animals that arrest development following the L2 stage and have dark, dauer-like intestines, but are not radially constricted like dauers and do not cease movement or pumping. Dauer-like animals such as these have also been seen in mutants of *daf-2* (Gems et al. 1998) and *age-1* (Gottlieb and Ruvkun 1994). For *pdk-1(sa709)* dauer formation assays, parents were allowed to lay eggs at room temperature for 5.5 hr and plates were then shifted to 26.8°C. Progeny were counted 41 hr post-egg-lay.

Paradis et al.

pdk-1(mg142) dauer formation assays

Gravid adults were allowed to lay eggs at 25°C for 3 hr. Progeny were scored for all classes at 48 hr post-egglay and some strains were scored at 72 or 96 hr post-egglay. For all assays performed in this study, numbers represent the summary of at least two trials of each genotype in at least two experiments performed on different days. In all assays, the following scoring categories were used. Dauer-like refers to animals that were arrested and had a dark intestine like *age-1* or *daf-2* dauers but were not as fully constricted as these dauers, or that were arrested and constricted like *age-1* and *daf-2* dauers but did not have as dark an intestine as *age-1* or *daf-2* dauers. The dauer-like category is equivalent to the partial dauer category in Paradis and Ruvkun (1998). 'Other' refers to animals that could not be classified as dauer because the animal was young, had a grossly aberrant morphology, or was dead.

Allele sequencing

Genomic DNA from *pdk-1(mg142)*, *pdk-1(sa680)*, and *pdk-1(sa709)* strains was PCR-amplified and directly sequenced. At least two different outcrossed *pdk-1(mg142)* and *pdk-1(sa680)* strains were sequenced.

cDNA characterization

pdk-1a gene structure was confirmed by sequencing of a cDNA (yk216b6 provided by Y. Kohara, National Institute of Genetics, Mishima, Japan). *pdk-1b* gene structure was confirmed by sequencing of cDNAs (yk478b12, yk499g8, yk551e8 provided by Y. Kohara). The 5' end of the gene was determined by 5' RACE (GIBCO) using a gene-specific primer to exon 4 and is assumed to be the same for both *pdk-1a* and *pdk-1b*. The *pdk-1* message analyzed by 5' RACE was *trans*-spliced with a SL1 leader sequence 10 bp upstream of the first methionine.

RNAi

The *pdk-1* coding region was amplified from yk478b12 (Y. Kohara) and RNA prepared as described (Paradis and Ruvkun 1998). Preparation of *akt-1* and *akt-2* RNAs and injections were performed as described (Paradis and Ruvkun 1998). After injection, the worms were allowed to recover at 20°C for 24 hr, then were moved to fresh plates and allowed to lay eggs at the appropriate temperature for 24 hr. Broods were scored for dead eggs 24-hr post-egglay and for dauers or L4 larvae and adults 48 hr post-egglay. For assays performed at 20°C only, a second consecutive 24-hr egglay at 20°C was performed and scored. We found slight differences between the dauer-inducing ability of *akt-1 + akt-2* RNAi in a fresh stock of N₂ wild-type strain received from the *C. elegans* Genetic Center and in N₂ that had been cultured in our lab [cf. Table 3 of this report with Table 2 of Paradis and Ruvkun (1998)]. We performed the *akt-1 + akt-2* RNAi assay at 26°C for greater consistency between assays in the new N₂ background. We suspect that either the presence of modifier mutations or fluctuations of temperature within incubators have affected penetrance of the Daf-c phenotype of *akt-1 + akt-2* RNAi.

Construction of pdk-1 transgenic lines and scoring of transgene effects on dauer formation

A 9.2-kb PCR product of genomic DNA from the *pdk-1(+)* genomic region containing 2.7 kb of 5' upstream regulatory sequence, 6.1 kb of coding sequence containing introns and exons, and 0.4 kb of *pdk-1* 3' UTR was purified using QIAquick

(Qiagen) and injected at 10 ng/μl with *ttx-3::GFP* at 50 ng/μl (pPD95.75-C40H5-GFP O. Hobert, MGH and Harvard Medical School) as a co-injection marker (Mello et al. 1991). *pdk-1(KD)* was constructed and injected in the same manner except PCR primers were used to introduce the K98N mutation. Once the arrays were established in wild type, they were crossed into an *age-1(mg44)* background. To score arrays in a wild-type background, gravid adults were allowed to lay eggs at 25°C for 3 hr. All animals were scored 72 hr post-egglay. To score arrays in an *age-1* background, gravid adults were allowed to lay eggs at 25°C for 5 hr. All animals were scored 72 hr post-egglay. For a description of the categories used in Table 4, see the '*pdk-1(mg142)* dauer formation assays' section of Materials and Methods. The numbers in Table 4 represent the tally of two independent transgenic lines of *pdk-1(KD)* (*mgEx464* and *mgEx465*) and three independent transgenic lines of *pdk-1(+)* (*mgEx467*, *mgEx468*, and *mgEx469*) for each genotype. This same *pdk-1* construct was injected with *ttx-3::GFP* into *sa680* and *sa709* strains to assay for rescue of the Daf-c phenotype (1/2 lines rescued *sa680* and 3/3 lines rescued *sa709*).

Life span assays

Animals were grown at 20°C until the L4 larval stage and then transferred to plates (10 animals/plate) containing 400 μM fluoro-deoxyuridine (Sigma) at 25°C. Animals were scored every 1–3 days subsequently and moved periodically to keep growth conditions mold free. Animals were scored as dead if they failed to respond to a gentle tap on the head and tail with a platinum wire. Life span is defined as the day animals were at the L4 larval stage ($t = 0$) to the day the animal was scored as dead. A *t*-test was performed to compare mean life spans of each strain pairwise.

PDK-1/GFP expression

The PDK-1/GFP translational fusion was constructed as follows. A 9-kb PCR product of genomic DNA from the *pdk-1* genomic region comprising 2.9 kb of 5' upstream regulatory region and 6.1 kb of coding region including exons and introns was fused by PCR in-frame to a GFP with *unc-54* 3'UTR PCR product from pPD95.75 (A. Fire, Carnegie Institute of Washington, Baltimore, MD). PCR products were purified using QIAquick (Qiagen) and injected with *rol-6* (pRF4, 100 ng/μl) as the coinjection marker (Mello et al. 1991). For UV microscopy, worms were anesthetized in 5 μM NaN₃ M9 buffer and mounted on a 2% agarose pad. Three independent transgenic lines (*mgEx479*, *mgEx480*, and *mgEx481*) were scored to determine the expression pattern of PDK-1/GFP.

PDK1 kinase activity assays

To generate the Ala-277-Val substitution in hPDK1, site-directed mutagenesis (Quickchange, Stratagene) was performed on the Myc.hPDK1 cDNA (Chou et al. 1998) using the following primers: SP170 5'-CCAGCTTGTGGTAGGACTCCAC and SP171 5'-GTGGGAGTCCTACCACAAGCTGG. To determine the protein kinase activity of the hPDK1 proteins, the cDNAs encoding Myc.hPDK1, Myc.hPDK1.K110N, and Myc.hPDK1.A277V were transiently transfected into 293T cells using the calcium phosphate method (Ausubel et al. 1998). Following the transfection protocol, cells were recovered for 48 hr in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum at 37°C in a 5% humidified CO₂ atmosphere. Cell monolayers were washed twice with ice-cold phosphate buffered saline, then lysed in a

1% NP-40 lysis buffer as described previously (Chou et al. 1998). HPDK1 was immunoprecipitated using the monoclonal anti-Myc antibody and immunoprecipitates washed stringently as described (Chou et al. 1998). The kinase assay was performed using 2 mg of a recombinant His-tagged full-length Akt/PKB purified to homogeneity from baculovirus-infected cells, in the presence of 10 μ M PtdIns-3,4,5-P₃/100 μ M phosphatidylserine and 100 μ M phosphatidylcholine (Chou et al. 1998). The kinase assay was stopped by addition of SDS sample buffer, and proteins resolved by SDS-polyacrylamide. Phosphorylated Akt/PKB was detected by autoradiography and on a Bio-Rad Molecular Imager for quantitation. Expression of hPDK1 was detected on a 7.5% SDS-polyacrylamide gel, transferred to nitro-cellulose and visualized using the anti-Myc antibody and ECL (Amersham). hPDK1 protein concentration was quantitated using a Bio-Rad Molecular Imager, and equal amounts of wild-type hPDK1, hPDK1. K11ON, and hPDK1. A277Val were used in the *in vitro* kinase assay.

Acknowledgments

We thank P. Delorme and Y. Liu for expert technical assistance; Y. Kohara for providing cDNAs; O. Hobert and B. Reinhart for help with cell identifications; J. Avruch for discussions on PDK1 in particular and insulin signaling in general; J. Hogan for help with the PDK1-PKA crystal structure comparison; and T. Inoue and members of the Ruvkun laboratory for helpful suggestions and critical reading of the manuscript. Some of the strains used in this study were provided by the *C. elegans* Genetics Center, which is supported by the National Center for Research Resources. M.A. is a Howard Hughes Medical Institute predoctoral fellow. This work was supported by the National Institutes of Health grant RO1AG14161 to G.R. and RO1CA75134 to A.T.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked 'advertisement' in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Alessi, D.R., M. Andjelkovic, B. Caudwell, P. Cron, N. Morrice, P. Cohen, and B.A. Hemmings. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. *EMBO J.* **15**: 6541–6551.
- Alessi, D.R., M. Deak, A. Casamayor, F.B. Caudwell, N. Morrice, D.G. Norman, P. Gaffney, C.B. Reese, C.N. MacDougall, D. Harbison, A. Ashworth, and M. Bownes. 1997a. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): Structural and functional homology with the *Drosophila* DSTPK61 kinase. *Curr. Biol.* **7**: 776–789.
- Alessi, D.R., S.R. James, C.P. Downes, A.B. Holmes, P.R.J. Gaffney, C.B. Reese, and P. Cohen. 1997b. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Ba. *Curr. Biol.* **7**: 261–269.
- Alessi, D.R., M.T. Kozlowski, Q.P. Weng, N. Morrice, and J. Avruch. 1998. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase *in vivo* and *in vitro*. *Curr. Biol.* **8**: 69–81.
- Anderson, K.E., J. Coadwell, L.R. Stephens, and P.T. Hawkins. 1998. Translocation of PDK1 to the plasma membrane is important in allowing PDK1 to activate protein kinase B. *Curr. Biol.* **8**: 684–691.
- Andjelkovic, M., D.R. Alessi, R. Meier, A. Fernandez, N.J. Lamb, M. Frech, P. Cron, P. Cohen, J.M. Lucocq, and B.A. Hemmings. 1997. Role of translocation in the activation and function of protein kinase B. *J. Biol. Chem.* **272**: 31515–31524.
- Apfeld, J. and C. Kenyon. 1998. Cell nonautonomy of *C. elegans daf-2* function in the regulation of diapause and life span. *Cell* **95**: 199–210.
- Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl. 1998. *Current protocols in molecular biology*. John Wiley and Sons, New York, NY.
- Avruch, J. 1998. Insulin signal transduction through protein kinase cascades. *Mol. Cell. Biochem.* **182**: 31–48.
- Bargmann, C.I. and H.R. Horvitz. 1991. Control of larval development by chemosensory neurons in *Caenorhabditis elegans*. *Science* **251**: 1243–1246.
- Brunet, A., A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden, J. Blenis, and M.E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* **96**: 857–868.
- Chalfie, M., Y. Tu, G. Euskirchen, W.W. Ward, and D.C. Prasher. 1994. Green fluorescent protein as a marker for gene expression. *Science* **263**: 802–805.
- Cheng, X., Y. Ma, M. Moore, B.A. Hemmings, and S.S. Taylor. 1998. Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. *Proc. Natl. Acad. Sci.* **95**: 9849–9854.
- Chou, M.M., W. Hou, J. Johnson, L.K. Graham, M.H. Lee, C.S. Chen, A.C. Newton, B.S. Schaffhausen, and A. Toker. 1998. Regulation of protein kinase C zeta by PI 3-kinase and PDK1. *Curr. Biol.* **8**: 1069–1077.
- Cross, D.A.E., D.R. Alessi, P. Cohen, M. Andjelkovich, and B.A. Hemmings. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* **378**: 785–789.
- Delcommenne, M., C. Tan, V. Gray, L. Rue, J. Woodgett, and S. Dedhar. 1998. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. *Proc. Natl. Acad. Sci.* **95**: 11211–11216.
- Dudek, H., S.R. Datta, T.F. Franke, M.J. Birnbaum, R. Yao, G.M. Cooper, R.A. Segal, D.R. Kaplan, and M.E. Greenberg. 1997. Regulation of neuronal survival by the serine-threonine protein kinase Akt. *Science* **275**: 661–665.
- Estevez, M., L. Attisano, J.L. Wrana, P.S. Albert, J. Massague, and D.L. Riddle. 1993. The *daf-4* gene encodes a bone morphogenetic protein receptor controlling *C. elegans* dauer larva development. *Nature* **365**: 644–649.
- Fire, A., S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello. 1998. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**: 806–811.
- Franke, T.F., D.R. Kaplan, L.C. Cantley, and A. Toker. 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science* **275**: 665–668.
- Frech, M., M. Andjelkovic, E. Ingley, K.K. Reddy, J.R. Falck, and B.A. Hemmings. 1997. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. *J. Biol. Chem.* **272**: 8474–8481.
- Gems, D., A.J. Sutton, M.L. Sundermeyer, P.S. Albert, K.V. King, M.L. Edgley, P.L. Larsen, and D.L. Riddle. 1998. Two pleiotropic classes of *daf-2* mutation affect larval arrest, adult behavior, reproduction and longevity in *Caenorhabditis elegans*. *Genetics* **150**: 129–155.
- Gottlieb, S. and G. Ruvkun. 1994. *daf-2*, *daf-16*, and *daf-23*: Genetically interacting genes controlling dauer formation in *Caenorhabditis elegans*. *Genetics* **137**: 107–120.

- Hanks, S.K. and T. Hunter. 1995. The eukaryotic protein kinase superfamily. In *The protein kinase facts book protein-serine kinases* (ed. G. Hardie and S. Hanks), pp. 7–47. Academic Press, Inc., San Diego, CA.
- Kahn, C.R. 1994. Insulin action, diabetogenes, and the cause of type II diabetes. *Diabetes* **43**: 1066–1084.
- Kauffmann-Zeh, A., P. Rodriguez-Viciana, E. Ulrich, C. Gilbert, P. Coffey, J. Downward, and G. Evan. 1997. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. *Nature* **385**: 544–548.
- Kenyon, C. 1997. Environmental factors and gene activities that influence life span. In *C. elegans II* (ed. D.L. Riddle, T. Blumenthal, B.J. Meyer, and J.R. Priess), pp. 791–813. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Kenyon, C., J. Chang, E. Gensch, A. Rudner, and R. Tabtlang. 1993. A *C. elegans* mutant that lives twice as long as wild type. *Nature* **366**: 461–464.
- Kimura, K., H.A. Tissenbaum, Y. Liu, and G. Ruvkun. 1997. *daf-2*, an insulin receptor-like gene that regulates longevity and diapause in *Caenorhabditis elegans*. *Science* **277**: 942–946.
- Klass, M. 1983. A method for the isolation of longevity mutants in the nematode *C. elegans* and initial results. *Mech. Ageing Dev.* **22**: 279–286.
- Klippel, A., W.M. Kavanaugh, D. Pot, and L.T. Williams. 1997. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. *Mol. Cell. Biol.* **17**: 338–344.
- Kohn, A.D., S.A. Summers, M.J. Birnbaum, and R.A. Roth. 1996. Expression of constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. *J. Biol. Chem.* **271**: 31372–31378.
- Kulik, G., A. Klippel, and M.J. Weber. 1997. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. *Mol. Cell. Biol.* **17**: 1595–1606.
- Larsen, P.L. 1993. Aging and resistance to oxidative damage in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci.* **90**: 8905–8909.
- Larsen, P.L., P.S. Albert, and D.L. Riddle. 1995. Genes that regulate both development and longevity in *Caenorhabditis elegans*. *Genetics* **139**: 1567–1583.
- Le Good, J.A., W.H. Ziegler, D.B. Parekh, D.R. Alessi, P. Cohen, and P.J. Parker. 1998. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. *Science* **281**: 2042–2045.
- Lin, K., J.B. Dorman, A. Rodan, and C. Kenyon. 1997. *daf-16*: An HNF-3/forkhead family member that can function to double the life-span of *Caenorhabditis elegans*. *Science* **278**: 1319–1322.
- Malone, E.A., T. Inoue, and J.H. Thomas. 1996. Genetic analysis of the roles of *daf-28* and *age-1* in regulating dauer formation. *Genetics* **143**: 1193–1205.
- Mello, C.C., J.M. Kramer, D. Stinchcomb, and V. Ambros. 1991. Efficient gene transfer in *C. elegans*: Extrachromosomal maintenance and integration transforming sequences. *EMBO J.* **10**: 3959–3970.
- Morris, J.Z., H.A. Tissenbaum, and G. Ruvkun. 1996. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in *Caenorhabditis elegans*. *Nature* **382**: 536–539.
- O’Riordan, V.B. and A.M. Burnell. 1989. Intermediary metabolism in the dauer larva of the nematode *Caenorhabditis elegans-1*. Glycolysis, gluconeogenesis, oxidative phosphorylation and the tricarboxylic acid cycle. *Comp. Biochem. Biophys.* **92B**: 223–238.
- . 1990. Intermediary metabolism in the dauer larva of the nematode *Caenorhabditis elegans-II*. The glyoxylate cycle and fatty acid oxidation. *Comp. Biochem. Physiol.* **95B**: 125–130.
- Ogg, S. and G. Ruvkun. 1998. The *C. elegans* PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. *Mol. Cell* **2**: 887–893.
- Ogg, S., S. Paradis, S. Gottlieb, G.I. Patterson, L. Lee, H.A. Tissenbaum, and G. Ruvkun. 1997. The fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in *C. elegans*. *Nature* **389**: 994–999.
- Paradis, S. and G. Ruvkun. 1998. *Caenorhabditis elegans* Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. *Genes & Dev.* **12**: 2488–2498.
- Pullen, N., P.B. Dennis, M. Andjelkovic, A. Dufner, S.C. Kozma, B.A. Hemmings, and G. Thomas. 1998. Phosphorylation and activation of p70s6k by PDK1. *Science* **279**: 707–710.
- Ren, P., C.-S. Lim, R. Johnsen, P.S. Albert, D. Pilgrim, and D.L. Riddle. 1996. Control of *C. elegans* larval development by neuronal expression of a TGF-beta homolog. *Science* **274**: 1389–1392.
- Riddle, D.L. 1988. The dauer larva. In *The nematode Caenorhabditis elegans* (ed. W.B. Wood), pp. 393–412. Cold Spring Harbor Press, Cold Spring Harbor, NY.
- Riddle, D.L. and P.S. Albert. 1997. Genetic and environmental regulation of dauer larva development. In *C. elegans II* (ed. D.L. Riddle, T. Blumenthal, B.J. Meyer, and J.R. Priess), pp. 739–768. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Riddle, D.L., M.M. Swanson, and P.S. Albert. 1981. Interacting genes in nematode dauer larva formation. *Nature* **290**: 668–671.
- Romanelli, A., K.A. Martin, A. Toker, and J. Blenis. 1999. p70 S6 kinase is regulated by protein kinase czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex. *Mol. Cell. Biol.* **19**: 2921–2928.
- Sohal, R.S. and R. Weindruch. 1996. Oxidative stress, caloric restriction, and aging. *Science* **273**: 59–63.
- Stephens, L., K. Anderson, D. Stokoe, H. Erdjument-Bromage, G.F. Painter, A.B. Holmes, P.R. Gaffney, C.B. Reese, F. McCormick, P. Tempst, J. Coadwell, and P.T. Hawkins. 1998. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. *Science* **279**: 710–714.
- Stokoe, D., L.R. Stephens, T. Copeland, P.R.J. Gaffney, C.B. Reese, G.F. Painter, A.B. Holmes, F. McCormick, and P.T. Hawkins. 1997. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. *Science* **277**: 567–570.
- Thomas, J.H., D.A. Birnby, and J.J. Vowels. 1993. Evidence for parallel processing of sensory information controlling dauer formation in *Caenorhabditis elegans*. *Genetics* **134**: 1005–1117.
- Toker, A. and L.C. Cantley. 1997. Signalling through the lipid products of phosphoinositide-3-OH kinase. *Nature* **387**: 673–676.
- Vowels, J.J. and J.H. Thomas. 1992. Genetic analysis of chemosensory control of dauer formation in *Caenorhabditis elegans*. *Genetics* **130**: 105–123.
- Zheng, J., D.R. Knighton, N.H. Xuong, S.S. Taylor, J.M. Sowadski, and L.F. Ten Eyck. 1993. Crystal structures of the myristylated catalytic subunit of cAMP-dependent protein kinase reveal open and closed conformations. *Protein Sci.* **2**: 1559–1573.



A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in *Caenorhabditis elegans*

Suzanne Paradis, Michael Ailion, Alex Toker, et al.

Genes Dev. 1999, **13**:

References

This article cites 53 articles, 28 of which can be accessed free at:
<http://genesdev.cshlp.org/content/13/11/1438.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

An advertisement banner for Dharmacon Reagents and Horizon. On the left, it says 'Dharmacon™ Reagents' with the tagline 'Custom synthesis, RNAi, and CRISPR solutions'. In the center, the text 'Infinite Reliability' is displayed in a large, white, sans-serif font. To the right of this text is a 'More' button. On the far right, the 'horizon' logo is shown in white, with 'a PerkinElmer company' written below it. The background of the banner features a colorful, abstract graphic of intertwined DNA or protein strands in shades of purple, blue, and green.